Macquarie Group Ltd. lowered its position in shares of uniQure NV (NASDAQ:QURE) by 5.2% during the second quarter, according to its most recent filing with the SEC. The fund owned 80,000 shares of the company’s stock after selling 4,400 shares during the period. Macquarie Group Ltd. owned about 0.32% of uniQure NV worth $590,000 at the end of the most recent reporting period.
Several other large investors have also added to or reduced their stakes in QURE. JPMorgan Chase & Co. boosted its stake in shares of uniQure NV by 68.5% in the second quarter. JPMorgan Chase & Co. now owns 14,174 shares of the company’s stock valued at $104,000 after buying an additional 5,760 shares during the last quarter. TFS Capital LLC boosted its stake in shares of uniQure NV by 3.0% in the second quarter. TFS Capital LLC now owns 15,156 shares of the company’s stock valued at $112,000 after buying an additional 437 shares during the last quarter. Princeton Alpha Management LP purchased a new stake in shares of uniQure NV during the second quarter valued at approximately $120,000. Fox Run Management L.L.C. purchased a new stake in shares of uniQure NV during the second quarter valued at approximately $122,000. Finally, Acrospire Investment Management LLC boosted its stake in shares of uniQure NV by 355.2% in the second quarter. Acrospire Investment Management LLC now owns 17,298 shares of the company’s stock valued at $127,000 after buying an additional 13,498 shares during the last quarter. 32.38% of the stock is currently owned by institutional investors.
uniQure NV (NASDAQ:QURE) opened at 7.99 on Tuesday. The stock’s market capitalization is $200.78 million. The firm’s 50-day moving average is $8.19 and its 200 day moving average is $10.21. uniQure NV has a 52-week low of $6.68 and a 52-week high of $22.93.
uniQure NV (NASDAQ:QURE) last issued its quarterly earnings data on Thursday, August 25th. The company reported ($0.87) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.02. uniQure NV had a negative net margin of 537.62% and a negative return on equity of 61.96%. On average, equities analysts forecast that uniQure NV will post ($3.70) earnings per share for the current year.
Several equities research analysts recently commented on QURE shares. Piper Jaffray Cos. set a $16.00 target price on uniQure NV and gave the stock a “buy” rating in a report on Friday, August 19th. Zacks Investment Research raised uniQure NV from a “sell” rating to a “hold” rating in a report on Wednesday, September 21st. Chardan Capital reissued a “buy” rating on shares of uniQure NV in a report on Monday, July 18th. Jefferies Group reissued a “buy” rating on shares of uniQure NV in a report on Tuesday, May 31st. Finally, Oppenheimer Holdings Inc. reissued a “buy” rating on shares of uniQure NV in a report on Tuesday, May 31st. One equities research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $28.10.
uniQure NV Company Profile
uniQure N.V. is engaged in the field of gene therapy. The Company is engaged in the discovery, development and commercialization of gene therapies. It has a technology platform that uses as the basis for collaborative product candidates across approximately three therapeutic focus areas, such as Liver/Metabolic Disease, Central Nervous System (CNS) Disease and Cardiovascular Disease.
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure NV (NASDAQ:QURE).
Receive News & Ratings for uniQure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure NV and related companies with MarketBeat.com's FREE daily email newsletter.